Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65,833,370
-
Total 13F shares
-
6,264,163
-
Share change
-
-188,911
-
Total reported value
-
$170,132,792
-
Price per share
-
$27.16
-
Number of holders
-
45
-
Value change
-
-$4,619,193
-
Number of buys
-
21
-
Number of sells
-
13
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q4 2025
As of 31 Dec 2025,
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) was held by
45 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,264,163 shares.
The largest 10 holders included
VANGUARD GROUP INC, Pictet Asset Management Holding SA, TSP Capital Management Group, LLC, UBS Group AG, Mirador Capital Partners LP, SG Americas Securities, LLC, Hennion & Walsh Asset Management, Inc., PROFUND ADVISORS LLC, TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY, and Universal- Beteiligungs- und Servicegesellschaft mbH.
This page lists
45
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.